Latest MS research news

Latest MS research news | 17 September 2013

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

The original phase III trial looked at oral laquinimod in 1106 people with RRMS.

From MSIF

Latest MS research news | 17 September 2013

Brain atrophy and lesion load predict long term disability in multiple sclerosis

This retrospective study as part of the MAGNIMS collaboration looked at MR imaging at baseline and after one year and two years as well as EDSS scores at baseline and after ten years in 261 people with MS.

From MSIF

Latest MS research news | 17 September 2013

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis

This study from the Netherlands looked at the validity and reliability over time of the Symbol Digit Modality Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) ...

From MSIF

Latest MS research news | 10 September 2013

Randomised controlled trial of a behavioural intervention targeting symptoms and physical activity in multiple sclerosis

This study group looked at promoting lifestyle physical activity in MS.

From MSIF

Latest MS research news | 10 September 2013

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

The researchers in this study evaluated the extent to which treatment effect on brain atrophy is able to mediate the effect on disability progression in RRMS at the clinical trial level.

From MSIF

Latest MS research news | 10 September 2013

Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development

This study looked at the plasma levels of osteopontin (OPN) in 492 people with MS, in order to evaluate its potential as a biomarker for disease ...

From MSIF

Latest MS research news | 03 September 2013

Immune competence after alemtuzumab treatment of multiple sclerosis

This pilot case control study looked at immunocompetence in 24 people with MS treated with alemtuzumab, which is a lymphodepleting anti-CD52 humanised monoclonal antibody.

From MSIF

Latest MS research news | 03 September 2013

Longitudinal MR imaging of iron in multiple sclerosis: An imaging marker of disease

This study investigated the relationship between MRI markers (phase imaging and transverse relaxation (R2*) mapping at 4.7T) of iron content and disease severity in 17 people with MS and 17 controls over a two-year period.

From MSIF

Latest MS research news | 03 September 2013

Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomised, double-blind trial

This study from Italy tested a home-based computerised programme for retraining attention dysfunction in MS.

From MSIF

Latest MS research news | 27 August 2013

Impaired decision-making and diffusion orientational complexity in people with multiple sclerosis

This study looked at cortical grey matter using a new measure of the number of diffusion orientations on diffusion MRI ‘diffusion orientation complexity (DOC)’ in areas known to be associated with performance on the Cambridge Gambling ...

From MSIF
 

Latest MS research news

Main MS research areas

Challenges of MS research

Atacicept in multiple sclerosis: a randomised, placebo-controlled, double-blind, phase 2 trial